Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma

Our plain-English summary of Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma, by X. Liao, C. Li, M. Huang, et al (Scientific Reports, 2026).

The study

• Authors: X. Liao, C. Li, M. Huang, Z. Yao, S. Luo, X. Lei
• Journal: Scientific Reports
• Published: 2026;16(1)
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer with limited treatment options and extremely poor survival outcomes. Due to the disease's low incidence, large-scale cohort studies to clarify survival outcomes and the impact of treatments like chemotherapy are limited. This study aimed to use conditional survival (CS) analysis to assess survival trends and explore the survival benefits of chemotherapy in MPM patients. Using SEER data (2000-2019), CS analysis was applied to capture survival probabilities conditional on having survived specific durations after diagnosis. Additionally, we used machine learning algorithms, including Random Survival Forest and the least absolute shrinkage and selection operator regression, combined with Cox proportional hazards models, to develop and validate a nomogram model for CS prediction. Propensity score matching (PSM) was conducted to evaluate the effect of chemotherapy on survival. Among 1,549 MPM patients, CS rates improved with time survived post-diagnosis but plateaued later, highlighting the need for early intervention and follow-up. The CS-based nomogram model demonstrated strong predictive performance, with C-index values of 0.701 and 0.717 in the training and validation cohorts, respectively. The model was well-calibrated, with AUC values indicating consistent predictive accuracy. DCA analysis validated the clinical applicability of the model. PSM analysis showed that chemotherapy was associated with longer overall survival. CS analysis provides a time-updated complement to traditional survival estimates and may inform follow-up intensity and patient counseling. The CS-based nomogram offers a useful adjunct to current staging for individualized risk assessment in MPM. Moreover, our study highlighted the potential survival benefit of chemotherapy, though further research is needed to confirm these findings.

© 2026. The Author(s).

In plain English

This study used SEER cancer registry records for 1,549 patients diagnosed with malignant peritoneal mesothelioma between 2000 and 2019. It did not examine asbestos exposure. The authors calculated "conditional survival": the chance of surviving further, given time already survived. One-year survival was 53%. The chance of reaching 5 years was 25% at diagnosis, rising to 46%, 61%, 75% and 86% for patients who had already survived 1, 2, 3 and 4 years. The gains flattened over time. The authors built a scoring chart (nomogram) from age, sex, tumor histology, stage, marital status, surgery and chemotherapy. Its C-index, a measure of how well it ranks patients by risk, was 0.701 in the group used to build it and 0.717 in a separate test group. The authors called this performance moderate and the tool complementary. After patients with and without chemotherapy were matched, chemotherapy was associated with longer overall survival. The authors called this finding exploratory, because the registry lacks treatment details and fitter patients may have been chosen for chemotherapy.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Retrospective cohort study using a population-based cancer registry (SEER), with conditional survival analysis, a prediction model (nomogram), and propensity score matching to compare patients with and without chemotherapy
• Who was studied: 1,549 patients with malignant peritoneal mesothelioma recorded in the SEER database and diagnosed between 2000 and 2019. They were split at random into a training set of 1,084 and a validation set of 465. Patients with missing surgery, survival status or survival duration data were excluded.
• Exposure: No asbestos or fiber exposure was studied. The treatment compared was chemotherapy versus no chemotherapy, in 1:1 matched groups. The prognostic factors examined included age, sex, race, tumor histology, stage, marital status, surgery, radiotherapy and chemotherapy.
• Main results:
  • Across all patients, mortality was highest in the first year after diagnosis, and one-year survival was 53%.
  • Across all patients, the probability of reaching 5-year survival was 25% at diagnosis. It was 46%, 61%, 75% and 86% for patients who had already survived 1, 2, 3 and 4 years.
  • The improvement in conditional survival flattened as more years passed.
  • The final model included age, sex, tumor histology, T stage, M stage, SEER stage, marital status, surgery and chemotherapy.
  • The nomogram's C-index was 0.701 in the training cohort and 0.717 in the validation cohort.
  • AUC values at 1, 3 and 5 years were 0.74, 0.76 and 0.79 in the training set, and 0.80, 0.79 and 0.75 in the validation set.
  • A risk score cutoff of 214 divided patients into high-risk and low-risk groups. Survival differed significantly between these groups in both the training and validation cohorts.
  • In the propensity-matched cohort, chemotherapy was associated with longer overall survival. The text gives no hazard ratio or confidence interval.
• The authors' conclusion: The authors concluded that the matched analysis suggested chemotherapy may provide a survival advantage, but that this needs further validation and should be considered exploratory and hypothesis-generating. They said the nomogram should be regarded as a complementary tool, not a standalone prognostic model.
• Limitations the authors state:
  • SEER does not record chemotherapy regimen, dose intensity, line of therapy, time of initiation, performance status or tumor burden, and chemotherapy is known to be under-reported in registry data.
  • Confounding by indication, such as fitter patients being given chemotherapy, cannot be removed by propensity score matching.
  • As a retrospective analysis, the study is subject to selection bias and missing data.
  • The model's ability to distinguish patients by risk was moderate.
  • The model needs external validation in prospective, multi-institutional studies.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma, Peritoneal mesothelioma.

Medical terms in this study, explained in our Lexicon: Peritoneal Mesothelioma, Chemotherapy, SEER, Overall Survival, Staging.

Related studies

• Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort — Y. Fang, M. Xiang, et al. (2024)
• Distant Metastatic Pattern and Its Prognostic Significance in Malignant Pleural Mesothelioma: A Population-Based Study Based on a Machine Learning Model — J. Yu, C. Peng, et al. (2025)
• Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma — Y. Wo, Y. Peng, et al. (2023)
• Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009 — M.J. Soeberg, N. Creighton, et al. (2016)
• Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma — A.M. Krasinskas, A.C. Borczuk, et al. (2016)
• Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival — V. Verma, R.L. Sleightholm, et al. (2018)

Browse more research in Scientific Reports, or return to medical research.